


## PHARMACEUTICAL 2018

## ENDOCYTE INC Rank 55 of 342







## PHARMACEUTICAL 2018



## **ENDOCYTE INC** Rank 55 of 342

The relative strengths and weaknesses of ENDOCYTE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDOCYTE INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 112% points. The greatest weakness of ENDOCYTE INC is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 160% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	98,573
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,546
Liabilities, Non-Current	0
Other Assets	7.1
Other Compr. Net Income	-23
Other Expenses	0
Other Liabilities	732
Other Net Income	1,112
Other Revenues	0
Property and Equipment	2,182
Research and Development	42,406
Selling, General and Administrative Expense	13,770

Output Variable	Value in 1000 USD
Assets	100,762
Liabilities	5,278
Expenses	56,176
Revenues	0
Stockholders Equity	95,484
Net Income	-55,064
Comprehensive Net Income	-55,076
Economic Capital Ratio	206%

